Latest News

STAT Plus: EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals

Seeking to end another flap about transparency, the European Medicines Agency has agreed to recommendations made by the European Ombudsman to ensure that private talks with drug makers about marketing applications do not influence approval decisions.

In a Nov. 21 letter to Ombudsman Emily O’Reilly, the regulator noted it plans to separate “to the greatest extent possible” the roles of its Scientific Advisory Working Group, which makes suggestions to drug makers about such things as clinical trial design, and the members of the Committee for Medicinal Products for Human Use, which evaluates marketing applications.

Continue to STAT Plus to read the full story…

Source link

Related posts

Mentalizing and depression


Plant-based diet may lower risk for heart disease


Modifiable risk factors play key roles in the development of gout


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World